Terazosin
Antineoplastic agent, antihypertensive agent, alpha-adrenergic antagonist. Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.
General
Type : Not AlphaBeta Hydrolase target, Drug, Quinazoline, Piperazine, Sulfur Compound
Chemical_Nomenclature : [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
Canonical SMILES : COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChI : InChI=1S\/C19H25N5O4\/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14\/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey : VCKUSRYTPJJLNI-UHFFFAOYSA-N
Other name(s) : Terazosine || Fosfomic || Terazosina
MW : 387.4
Formula : C19H25N5O4
CAS_number : 63590-64-7
PubChem : 5401
UniChem : VCKUSRYTPJJLNI-UHFFFAOYSA-N
Target
Families : Terazosin ligand of proteins in family
Monoglyceridelipase_lysophospholip
Protein :
human-MGLL
References (1)
| Title : Targeting MGLL: Terazosin Regulates Glycerolipid Metabolism to Mitigate Endothelial Cell Senescence - Huang_2025_J.Lipid.Res__100904 |
| Author(s) : Huang J , Yan J , Wan Z , Ji T , Li H , Liang W , Huang Y , Yang Z , Xiao Y , Nie H , Zhang C |
| Ref : J Lipid Res , :100904 , 2025 |
| Abstract : |
| PubMedSearch : Huang_2025_J.Lipid.Res__100904 |
| PubMedID: 40972970 |
| Gene_locus related to this paper: mouse-ABHD6 |